These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17499480)

  • 1. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone.
    Buckley PF; Harvey PD; Bowie CR; Loebel A
    Schizophr Res; 2007 Aug; 94(1-3):99-106. PubMed ID: 17499480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements.
    Harvey PD; Green MF; Bowie C; Loebel A
    Psychopharmacology (Berl); 2006 Aug; 187(3):356-63. PubMed ID: 16783539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia.
    Harvey PD; Meltzer H; Simpson GM; Potkin SG; Loebel A; Siu C; Romano SJ
    Schizophr Res; 2004 Feb; 66(2-3):101-13. PubMed ID: 15061242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?
    Malhotra AK; Burdick KE; Razi K; Bates JA; Sanders M; Kane JM
    Schizophr Res; 2006 Oct; 87(1-3):181-4. PubMed ID: 16820282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in prosocial functioning after a switch to ziprasidone treatment.
    Loebel A; Siu C; Romano S
    CNS Spectr; 2004 May; 9(5):357-64. PubMed ID: 15115948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.
    van Veelen NM; Grootens KP; Peuskens J; Sabbe BG; Salden ME; Verkes RJ; Kahn RS; Sitskoorn MM
    Schizophr Res; 2010 Jul; 120(1-3):191-8. PubMed ID: 20493663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.
    Rossi A; Vita A; Tiradritti P; Romeo F
    Int Clin Psychopharmacol; 2008 Jul; 23(4):216-22. PubMed ID: 18545060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Harvey PD; Siu CO; Romano S
    Psychopharmacology (Berl); 2004 Mar; 172(3):324-32. PubMed ID: 14615877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].
    Tybura P; Mak M; Samochowiec A; Pełka-Wysiecka J; Grzywacz A; Grochans E; Zaremba-Pechmann L; Samochowiec J
    Psychiatr Pol; 2013; 47(4):567-78. PubMed ID: 24946464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.
    Masand P; O'Gorman C; Mandel FS
    Schizophr Res; 2011 Mar; 126(1-3):174-83. PubMed ID: 21185155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment.
    Harvey PD; Sacchetti E; Galluzzo A; Romeo F; Gorini B; Bilder RM; Loebel AD
    Schizophr Res; 2008 Oct; 105(1-3):138-43. PubMed ID: 18077136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone and cognition: the evolving story.
    Harvey PD
    J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms.
    Gurpegui M; Alvarez E; Bousoño M; Ciudad A; Carlos Gómez J; Olivares JM
    Eur Neuropsychopharmacol; 2007 Nov; 17(11):725-34. PubMed ID: 17543505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
    Weiden PJ; Newcomer JW; Loebel AD; Yang R; Lebovitz HE
    Neuropsychopharmacology; 2008 Apr; 33(5):985-94. PubMed ID: 17637612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.